News
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they contract respiratory syncytial virus. Previously the vaccine, sold under the name mResvia, was only licensed for use in adults aged 60 and older.
While it is not the most common allergy in the country, almost 2 million Americans have an allergy to soy, according to Food ...
This story is from the next print edition of MIT Technology Review, which explores power—who has it, and who wants it. It’s ...
WEDNESDAY, June 11, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) says it plans to use artificial ...
The FDA plans to "unleash AI" on new drug evaluations in order to "radically increase efficiency in the review process." ...
With a Trump-driven reduction of nearly 2,000 employees, agency officials view artificial intelligence as a way to speed ...
Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. | ...
The federal government plans to develop a new definition of ultraprocessed foods, a wide-ranging group of snacks, meals and ...
A new article in the Journal of the American Medical Association said the FDA will implement AI into multiple processes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback